This group is for elite investors and traders that are dedicated to participating in an active community that wants to learn from each other, share their research, and work together to do deep analysis of securities. The moderator of this group taught securities analysis at UCLA and is dedicated to helping other investors improve their abilities.
In this private group, membership is restricted and regular contributions are required. Any member not contributing on a regular basis will be removed to make room for a new member.
In your application messsage, please share your background and what you can contribute to the group.
Company Overview and News
MannKind (MNKD) investors have now seen the sales of Afrezza under the control of the company for 2 full years. In that time the company has increased sales of Afrezza at a pace much slower than would be needed to deliver equity appreciation, which in turn makes equity offerings at desired prices difficult, and the result is a company that remains cash strapped and unable to find a partner at terms that would lift the weight of marketing the drug off of the shoulders of MannKind.
MannKind (MNKD) announced today via an 8-K SEC filing that the company has negotiated the terms of Deerfield debt again and as a result has issued 7,367,839 shares to handle some of the payment that was due on July 18th of this year. The company had $10,000,000 due and erased $7,000,000 of that obligation with this transaction. The other $3,000,000 has been deferred to August 31st of 2018. That amount can be paid with shares (at the option of Deerfield) at a price of $1.
The short interest data are out for the most recent settlement date, June 29. Generally speaking, companies within the biotech industry are considered to be a riskier group of stocks, with big potential upside and big potential downside.
MNKD AMGN CELGZ BIIB GILD ALXN CELG
Liquidia Technologies (LQDA), has filed the necessary paperwork with the SEC to make an initial public offering. The biopharma company is seeking to raise at least $57 million and will trade on the NASDAQ Capital Market. Jefferies and Cowen will run the book on the IPO.
MNKD ARNA GSK HRTX AERI UTHR INSM ALIOY GSK DRRX
The short interest data are out for the most recent settlement date, June 15. Generally speaking, companies within the biotech industry are considered to be a riskier group of stocks, with big potential upside and big potential downside.
MNKD AMGN CELGZ BIIB GILD ALXN CELG
Investors in MannKind Corporation (MNKD - Free Report) need to pay close attention to the stock based on moves in the options market lately. That is because the Jan 18, 2019 $5.00 Put had some of the highest implied volatility of all equity options today. What is Implied Volatility? Implied volatility shows how much movement the market is expecting in the future. Options with high levels of implied volatility suggest that investors in the underlying stocks are expecting a big move in one direction or the other.
WESTLAKE VILLAGE, Calif., June 25, 2018 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq:MNKD), a company focused on the development and commercialization of inhaled therapeutic products for patients with diseases such as diabetes and pulmonary arterial hypertension, today announced it is set to join the broad-market Russell 3000® Index at the conclusion of the Russell U.S. Indexes annual reconstitution, effective after the U.
WESTLAKE VILLAGE, Calif., June 23, 2018 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq:MNKD) announced that new data for Afrezza from the STAT study (STudy comparing prandial insulin Aspart vs. Technosphere insulin in patients with Type 1 diabetes on multiple daily injections) were released today at the American Diabetes Association’s 78th Scientific Sessions, being held June 22-26, 2018, in Orlando, Florida.
Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning. Trade battles are set to dominate another week's action, with a set of hair-trigger responses from former trade allies leading world news though threatened tariffs are still small in the face of a $20T U.
CTRV STZ.B GIS GAIN WBA MS.PRE PS MS.PRF MS.PRG MS.PRA NKE NSM NTRS TWTR CAG MS SONC AKAO AKAM CBAY GWP BAC TMUS SBHMY CCL STZ VTIQU CMG GWPH MS.PRI MS.PRK WMIH VTIQ NTRA QCOM PRGS MNKD WFCNP NTRSP RAD MCK WFC.PRL GAINM WFC.PRJ PIR TEP GADDP TEGP BAC WFC.PRT GS ATRC WFC.PRR WFC.PRQ LEA WFC.PRP BIIB WFC.PRO FII WFC.PRN MKC AAPL CCL HEI ACN WFC.PRY WFC.PRX BIDU WFC.PRW DRRX BBBY DIS WFC.PRV PAYX WFC WFC.WS C MD CMCSA COOL PTIE SNX SRE.PRA BLK S SBKO JPM SRE SNE INFO TMCX
Let's start off this week's MannKind (MNKD) discussion with the American Diabetes Association Conference, which started June 22 and runs through June 26. MannKind participated in the conference, had a booth there, presented posters, and also discussed Afrezza with attendees. The bigger pieces of news from the conference involved a STAT study that looked at achieving better time in range for blood glucose levels, while a second poster looked at hypoglycemia events.
MannKind’s Chief Medical Officer Presenting New Afrezza® Data Released at American Diabetes Association’s 78th Scientific Sessions
2017-10-16 - Asif
MannKind Corporation is a biopharmaceutical company focused on the discovery, development, and commercialization of therapeutic products for diseases such as diabetes. Its only approved product, Afrezza, is a rapid-acting inhaled insulin that was approved by the FDA on June 27, 2014 to improve glycemic control in adult patients with diabetes. Afrezza became available by prescription in United States retail pharmacies in February 2015. According to the Centers for Disease Control and Prevention, 30.3 million people in the United States had diabetes in 2015. Globally, the International Diabetes Federation has estimated that approximately 415.0 million people had diabetes in 2015 and approximately 642.0 million people will have diabetes by 2040. Afrezza is a rapid-acting inhaled insulin used to control high blood sugar in adults with type 1 and type 2 diabetes. The product consists of a dry powder formulation of human insulin delivered from a small portable inhaler. Administered at the...
47m - Asif
History and Development of the Company Kitov Pharma was incorporated under the laws of the State of Israel (under a previous name) on August 12, 1968 and its ordinary shares were originally listed for trading on the TASE in 1978. The company's ordinary shares are currently traded on the TASE under the symbol “KTOV”, and its ADSs and its public warrants are traded on NASDAQ under the symbols “KTOV” and “KTOVW”, respectively. In October 2012, the District Court in Lod, Israel approved the creditors arrangement in accordance with Section 350 of the Companies Law in order to effectuate the sale by Kitov Pharma (then known as Mainrom Line Logistics Ltd.) of all its activities, assets, rights, obligations and liabilities to a private company held by its then controlling shareholders, and all rights of Kitov Pharma’s creditors against it were extinguished. The sale was made pursuant to an arrangement between Kitov Pharma and its creditors. Following such sale and a related cash...
2h - Asif
Overview and Recent Developments Athersys is an international biotechnology company that is focused primarily in the field of regenerative medicine. The company's MultiStem® cell therapy, a patented and proprietary allogeneic stem cell product, is its lead platform product and is currently in later-stage clinical development. The company's current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients, particularly in the critical care segment. Current Programs By applying its proprietary MultiStem cell therapy product, the company established therapeutic product development programs treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. The company's programs in the clinical development stage include ...
22h - Asif
General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...
Silicon Investor Message Boards
This table lists all message boards related to MNKD / MannKind Corp. on message board site Silicon Investor.
as of ET